Tag: Pharma & Biotech
Successful R&D strategies aren’t always able to avoid every wrong turn, but they do steer clear of dead ends. Incorporating optionality into clinical development can enable companies to surmount unanticipated challenges and clinical trial setbacks. This paper will discuss how flexibility in clinical development can be incorporated at various points along an asset’s life cycle and how to avoid the kinds of decisions that will irrevocably shunt development programs down a single, narrowly defined path, resulting in all-or-nothing outcomes that kill, delay, or increase the cost of future development.
By providing my email address, I agree to ClearView's online policies